危重疾病期间肠内蛋白增强:靶蛋白随机临床试验。

IF 63.1 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Matthew J Summers, Lee-Anne S Chapple, Amalia Karahalios, Rinaldo Bellomo, Marianne J Chapman, Suzie Ferrie, Mark E Finnis, Craig French, Sally Hurford, Nima Kakho, Matthew J Maiden, Stephanie N O'Connor, Sandra L Peake, Jeffrey J Presneill, Emma J Ridley, An Tran-Duy, Patricia J Williams, Paul J Young, Sophie Zaloumis, Adam M Deane
{"title":"危重疾病期间肠内蛋白增强:靶蛋白随机临床试验。","authors":"Matthew J Summers, Lee-Anne S Chapple, Amalia Karahalios, Rinaldo Bellomo, Marianne J Chapman, Suzie Ferrie, Mark E Finnis, Craig French, Sally Hurford, Nima Kakho, Matthew J Maiden, Stephanie N O'Connor, Sandra L Peake, Jeffrey J Presneill, Emma J Ridley, An Tran-Duy, Patricia J Williams, Paul J Young, Sophie Zaloumis, Adam M Deane","doi":"10.1001/jama.2025.9110","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Guidelines recommend augmenting enteral protein during critical illness, but the impact on patient outcomes is uncertain.</p><p><strong>Objective: </strong>To determine whether augmenting enteral protein increases days alive and free from hospitalization.</p><p><strong>Design, setting, and participants: </strong>This cluster randomized, crossover, open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23, 2022, to August 23, 2023, with final follow-up on November 21, 2023.</p><p><strong>Intervention: </strong>Two isocaloric enteral formulae were compared: augmented protein (100 g protein/L) vs usual protein (63 g protein/L). ICUs used formulae sequentially for 3 months over a 12-month period; 4 ICUs commenced with augmented protein and 4 commenced with usual protein.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was the number of days free of admittance to the index hospital and alive at day 90. Secondary outcomes included days free of the index hospital at day 90 in survivors; alive at day 90; durations of invasive ventilation, ICU, and hospital admission; incidences of tracheostomy insertion and new kidney replacement therapy; and hospital discharge destination.</p><p><strong>Results: </strong>A total of 3397 patients were included (median [IQR] age, 61 (48-71) years; 2157 [64%] male). The median (IQR) number of days free of the index hospital and alive at day 90 was 62 (0-77) days in the augmented protein group and 64 (0-77) days in the usual protein group, with an adjusted-for-period between-group median difference of -1.97 (95% CI, -7.24 to 3.30) days (P = .46). At day 90, a total of 1221 of 1681 patients (72.6%) were alive in the augmented protein group and 1269 of 1716 (74.0%) were alive in the usual protein group (risk ratio, 0.99 [95% CI, 0.95-1.03]). Between-group differences for secondary outcomes included the following: difference in median days free of hospital in survivors, 0.01 (95% CI, -1.94 to 1.96) days; difference in mean duration of invasive ventilation, 6.8 (95% CI, -3.0 to 16.5) hours; cause-specific hazard ratios for durations of ICU admission (time to live ICU discharge), 0.93 (95% CI, 0.88-1.00) and hospital admission (time to live hospital discharge), 0.96 (95% CI, 0.90-1.02); and risk ratio for tracheostomy, 1.15 (95% CI, 0.66-2.01) and new kidney replacement therapy, 0.97 (95% CI, 0.81-1.16). Discharge destinations were similar.</p><p><strong>Conclusions and relevance: </strong>Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90.</p><p><strong>Trial registration: </strong>ANZCTR Identifier: ACTRN12621001484831.</p>","PeriodicalId":54909,"journal":{"name":"Jama-Journal of the American Medical Association","volume":" ","pages":"319-328"},"PeriodicalIF":63.1000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159859/pdf/","citationCount":"0","resultStr":"{\"title\":\"Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical Trial.\",\"authors\":\"Matthew J Summers, Lee-Anne S Chapple, Amalia Karahalios, Rinaldo Bellomo, Marianne J Chapman, Suzie Ferrie, Mark E Finnis, Craig French, Sally Hurford, Nima Kakho, Matthew J Maiden, Stephanie N O'Connor, Sandra L Peake, Jeffrey J Presneill, Emma J Ridley, An Tran-Duy, Patricia J Williams, Paul J Young, Sophie Zaloumis, Adam M Deane\",\"doi\":\"10.1001/jama.2025.9110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Guidelines recommend augmenting enteral protein during critical illness, but the impact on patient outcomes is uncertain.</p><p><strong>Objective: </strong>To determine whether augmenting enteral protein increases days alive and free from hospitalization.</p><p><strong>Design, setting, and participants: </strong>This cluster randomized, crossover, open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23, 2022, to August 23, 2023, with final follow-up on November 21, 2023.</p><p><strong>Intervention: </strong>Two isocaloric enteral formulae were compared: augmented protein (100 g protein/L) vs usual protein (63 g protein/L). ICUs used formulae sequentially for 3 months over a 12-month period; 4 ICUs commenced with augmented protein and 4 commenced with usual protein.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was the number of days free of admittance to the index hospital and alive at day 90. Secondary outcomes included days free of the index hospital at day 90 in survivors; alive at day 90; durations of invasive ventilation, ICU, and hospital admission; incidences of tracheostomy insertion and new kidney replacement therapy; and hospital discharge destination.</p><p><strong>Results: </strong>A total of 3397 patients were included (median [IQR] age, 61 (48-71) years; 2157 [64%] male). The median (IQR) number of days free of the index hospital and alive at day 90 was 62 (0-77) days in the augmented protein group and 64 (0-77) days in the usual protein group, with an adjusted-for-period between-group median difference of -1.97 (95% CI, -7.24 to 3.30) days (P = .46). At day 90, a total of 1221 of 1681 patients (72.6%) were alive in the augmented protein group and 1269 of 1716 (74.0%) were alive in the usual protein group (risk ratio, 0.99 [95% CI, 0.95-1.03]). Between-group differences for secondary outcomes included the following: difference in median days free of hospital in survivors, 0.01 (95% CI, -1.94 to 1.96) days; difference in mean duration of invasive ventilation, 6.8 (95% CI, -3.0 to 16.5) hours; cause-specific hazard ratios for durations of ICU admission (time to live ICU discharge), 0.93 (95% CI, 0.88-1.00) and hospital admission (time to live hospital discharge), 0.96 (95% CI, 0.90-1.02); and risk ratio for tracheostomy, 1.15 (95% CI, 0.66-2.01) and new kidney replacement therapy, 0.97 (95% CI, 0.81-1.16). Discharge destinations were similar.</p><p><strong>Conclusions and relevance: </strong>Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90.</p><p><strong>Trial registration: </strong>ANZCTR Identifier: ACTRN12621001484831.</p>\",\"PeriodicalId\":54909,\"journal\":{\"name\":\"Jama-Journal of the American Medical Association\",\"volume\":\" \",\"pages\":\"319-328\"},\"PeriodicalIF\":63.1000,\"publicationDate\":\"2025-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159859/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jama-Journal of the American Medical Association\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jama.2025.9110\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jama-Journal of the American Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jama.2025.9110","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

重要性:指南建议在危重疾病期间增加肠内蛋白,但对患者预后的影响尚不确定。目的:探讨增加肠内蛋白是否能增加存活和出院天数。设计、环境和参与者:该随机、交叉、开放标签试验于2022年5月23日至2023年8月23日在澳大利亚和新西兰的8个重症监护病房(icu)招募接受肠内营养的危重患者,最终随访时间为2023年11月21日。干预:比较两种等热量肠内配方:增强蛋白(100 g蛋白/L)与常规蛋白(63 g蛋白/L)。icu在12个月期间连续使用3个月的配方;4个icu以扩增蛋白开始,4个以正常蛋白开始。主要观察指标:主要观察指标为出院天数和90天存活天数。次要结局包括幸存者在第90天离开索引医院的天数;第90天存活;有创通气、ICU和住院时间;气管切开术与新肾替代治疗的发生率和出院目的地。结果:共纳入3397例患者(中位[IQR]年龄61(48-71)岁;2157[64%]男性)。在第90天,增强蛋白组脱离指标医院和存活的中位数(IQR)天数为62(0-77)天,普通蛋白组为64(0-77)天,调整后的组间中位数差异为-1.97 (95% CI, -7.24至3.30)天(P = 0.46)。第90天,增强蛋白组1681例患者中有1221例(72.6%)存活,普通蛋白组1716例患者中有1269例(74.0%)存活(风险比0.99 [95% CI, 0.95-1.03])。次要结局的组间差异包括:幸存者中位出院天数的差异为0.01 (95% CI, -1.94至1.96)天;有创通气的平均持续时间差异为6.8小时(95% CI, -3.0 ~ 16.5);ICU住院时间(ICU存活出院时间)的病因特异性风险比为0.93 (95% CI, 0.88-1.00),住院时间(存活出院时间)的病因特异性风险比为0.96 (95% CI, 0.90-1.02);气管切开术的风险比为1.15 (95% CI, 0.66-2.01),新的肾脏替代治疗的风险比为0.97 (95% CI, 0.81-1.16)。出院目的地相似。结论及相关性:危重期增加肠内蛋白并不能提高出院天数和90天生存率。试验注册:ANZCTR标识符:ACTRN12621001484831。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical Trial.

Importance: Guidelines recommend augmenting enteral protein during critical illness, but the impact on patient outcomes is uncertain.

Objective: To determine whether augmenting enteral protein increases days alive and free from hospitalization.

Design, setting, and participants: This cluster randomized, crossover, open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23, 2022, to August 23, 2023, with final follow-up on November 21, 2023.

Intervention: Two isocaloric enteral formulae were compared: augmented protein (100 g protein/L) vs usual protein (63 g protein/L). ICUs used formulae sequentially for 3 months over a 12-month period; 4 ICUs commenced with augmented protein and 4 commenced with usual protein.

Main outcomes and measures: The primary outcome was the number of days free of admittance to the index hospital and alive at day 90. Secondary outcomes included days free of the index hospital at day 90 in survivors; alive at day 90; durations of invasive ventilation, ICU, and hospital admission; incidences of tracheostomy insertion and new kidney replacement therapy; and hospital discharge destination.

Results: A total of 3397 patients were included (median [IQR] age, 61 (48-71) years; 2157 [64%] male). The median (IQR) number of days free of the index hospital and alive at day 90 was 62 (0-77) days in the augmented protein group and 64 (0-77) days in the usual protein group, with an adjusted-for-period between-group median difference of -1.97 (95% CI, -7.24 to 3.30) days (P = .46). At day 90, a total of 1221 of 1681 patients (72.6%) were alive in the augmented protein group and 1269 of 1716 (74.0%) were alive in the usual protein group (risk ratio, 0.99 [95% CI, 0.95-1.03]). Between-group differences for secondary outcomes included the following: difference in median days free of hospital in survivors, 0.01 (95% CI, -1.94 to 1.96) days; difference in mean duration of invasive ventilation, 6.8 (95% CI, -3.0 to 16.5) hours; cause-specific hazard ratios for durations of ICU admission (time to live ICU discharge), 0.93 (95% CI, 0.88-1.00) and hospital admission (time to live hospital discharge), 0.96 (95% CI, 0.90-1.02); and risk ratio for tracheostomy, 1.15 (95% CI, 0.66-2.01) and new kidney replacement therapy, 0.97 (95% CI, 0.81-1.16). Discharge destinations were similar.

Conclusions and relevance: Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90.

Trial registration: ANZCTR Identifier: ACTRN12621001484831.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
48.20
自引率
0.90%
发文量
1569
审稿时长
2 months
期刊介绍: JAMA (Journal of the American Medical Association) is an international peer-reviewed general medical journal. It has been published continuously since 1883. JAMA is a member of the JAMA Network, which is a consortium of peer-reviewed general medical and specialty publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信